000K utf8 1100 2025$c2025-06-20 1500 eng 2050 urn:nbn:de:gbv:27-dbt-66635-1 2051 10.3389/fonc.2025.1577859 3000 Akhtar, Mst Nasrin 3010 Chen, Yuan 3010 Clement, Joachim H. 3010 Gaßler, Nikolaus 3010 Hochhaus, Andreas 3010 Hofmann, Gunther O. 3010 Katenkamp, Kathrin 3010 Lehmann, Thomas 3010 Schrenk, Karin G. 3010 Spiegel, Christian 3010 Vogt, Matthias 3010 Walter, Annabell 3010 Weschenfelder, Wolfram 4000 MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma [Akhtar, Mst Nasrin] 4060 12 Seiten 4209 Background: Leiomyosarcoma is an aggressive tumor with a high rate of distant metastasis and poor prognosis. No standardized biomarkers are available to assess early diagnosis or monitoring during the clinical course. MicroRNAs (miRNAs) function in modulating a multitude of targets and are involved in tumorigenesis, cancer progression, and metastasis. This study was designed to evaluate miR-221, miR-320a, miR-133a, and miR-133b as potential biomarkers in leiomyosarcoma. Materials and methods: The expression levels of miR-221, miR-320a, miR-133a, and miR-133b as well as their target mRNAs CDKN1B , TGFBR1 , and IGF1R were assessed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) in tissue samples from 33 patients with leiomyosarcoma. Wilcoxon test, Kruskal-Wallis test, Mann-Whitney test as well as Spearman-Rho-test were used for statistical analysis. Receiver operating characteristic (ROC) analyses were performed to discriminate metastatic risk of local and primary tumors in correlation to miR-221, miR-320a, miR-133a, and miR-133b. Results: and discussion The expression levels of miR-221, miR-320a, and miR-133a were significantly upregulated in leiomyosarcoma tumor tissue compared to adjacent non-tumor tissue (p = 0.003 for miR-221, p = 0.006 for miR-320a, and p = 0.044 for miR-133a respectively). The target mRNAs CDKN1B , TGFBR1 , and IGF1R in 25 leiomyosarcoma tumor tissues were not significantly deregulated. There was no significant upregulation in primary tumors and metastases compared to local tumors for miR-221, miR-320a, miR-133a, and miR-133b. ROC curves of miRNA-221, miR-320a, miR-133a, and miR-133b to predict metastatic risk at initial presentation of the tumor, comparing non-metastasizing and metastasizing leiomyosarcomas, demonstrated no significant levels. Conclusion: miR-221, miR-320a, and miR-133a were significantly upregulated in leiomyosarcoma tumor tissue as compared to adjacent non-tumor tissue. There was no significant difference in miRNA expression and ROC curves in primary tumors as compared to local tumors. While not statistically significant, ROC curve of miR-133b suggests a potential role in predicting metastatic risk, warranting subsequent analysis. This study provides evidence for further evaluation of miR-221, miR-320a, miR-133a, and miR-133b as biomarkers in primary diagnosis and assessment of metastatic risk in leiomyosarcoma. 4950 https://doi.org/10.3389/fonc.2025.1577859$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:gbv:27-dbt-66635-1$xR$3Volltext$534 4961 https://www.db-thueringen.de/receive/dbt_mods_00066635 5051 610 5550 biomarkers 5550 miR-133a 5550 miR-133b 5550 miR-221 5550 miR-320a 5550 miRNA 5550 sarcoma